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ABSTRACT Clostridium difﬁcile infection (CDI) is becoming less exclusively a health
care-associated CDI (HA-CDI). The incidence of community-associated CDI (CA-CDI)
has increased over the past few decades. It has been postulated that asymptomatic
toxigenic C. difﬁcile (TCD)-colonized patients may play a role in the transfer of C. dif-
ﬁcile between the hospital setting and the community. Thus, to investigate the relat-
edness of C. difﬁcile across the hospital and community settings, we compared the
characteristics of symptomatic and asymptomatic host patients and the pathogens
from these patients in these two settings over a 3-year period. Two studies were si-
multaneously conducted; the ﬁrst study enrolled symptomatic CDI patients from two
tertiary care hospitals and the community in two Australian states, while the second
study enrolled asymptomatic TCD-colonized patients from the same tertiary care
hospitals. A total of 324 patients (96 with HA-CDI, 152 with CA-CDI, and 76 colo-
nized with TCD) were enrolled. The predominant C. difﬁcile ribotypes isolated in the
hospital setting corresponded with those isolated in the community, as it was found
that for 79% of the C. difﬁcile isolates from hospitals, an isolate with a matching ri-
botype was isolated in the community, suggesting that transmission between these
two settings is occurring. The toxigenic C. difﬁcile strains causing symptomatic infec-
tion were similar to those causing asymptomatic infection, and patients exposed to
antimicrobials prior to admission were more likely to develop a symptomatic infec-
tion (odds ratio, 2.94; 95% conﬁdence interval, 1.20 to 7.14). Our ﬁndings suggest
that the development of CDI symptoms in a setting without establishment of hospi-
tal epidemics with binary toxin-producing C. difﬁcile strains may be driven mainly by
host susceptibility and exposure to antimicrobials, rather than by C. difﬁcile strain
characteristics.
KEYWORDS Clostridium difﬁcile, asymptomatic, community-acquired infections,
health care-acquired infection, ribotyping
Over the past 3 decades, the epidemiology of Clostridium difﬁcile infection (CDI) hasmarkedly changed, and several countries have reported a signiﬁcant increase in
the incidence and severity of the disease as well as numerous hospital outbreaks. The
changes have been partly attributed to the emergence of speciﬁc C. difﬁcile strains (PCR
ribotypes 001, 027, and 078) with increased toxin production and in some cases
resistance to newer ﬂuoroquinolones (1–3). CDI was previously exclusively considered
a health care-associated CDI (HA-CDI) affecting elderly patients with multiple comor-
bidities and a recent history of antimicrobial exposure. However, patients in the
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community are now also considered at risk of CDI, and C. difﬁcile strains that are known
to be highly pathogenic are now frequently isolated from patients with community-
associated CDI (CA-CDI) (1). Severe cases of CA-CDI were reported among populations
that were considered at low risk of CDI, including pregnant women and healthy young
adults without antimicrobial exposure or contact with health care facilities (4, 5).
Symptoms of CDI can range from mild diarrhea to life-threatening conditions, such
as pseudomembranous colitis, and are precipitated by the capacity of some C. difﬁcile
strains to produce toxins A and B and binary toxin (CDT). Similar to other infectious
diseases, not all patients colonized with toxigenic C. difﬁcile (TCD) strains become
symptomatic. Loo et al. found that C. difﬁcile ribotype 027 was the predominant strain
isolated from symptomatic patients with HA-CDI, whereas asymptomatic patients were
more likely to be colonized with other strains (6). However, it is unclear which host and
pathogen features determine whether a patient colonized with C. difﬁcile will remain
asymptomatic or develop mild or severe forms of the disease in a setting where
non-ribotype 027 strains are endemic. Although cases of C. difﬁcile ribotype 027
infection have been reported in Australia (7, 8), C. difﬁcile ribotype 027 has not yet
become established, and the most common ribotypes circulating are 014/020, 056, and
002 (9, 10).
It has also been proposed that asymptomatic TCD-colonized patients act as a source
of environmental contamination and may result in the emergence of new CDI cases,
particularly in a hospital setting (11, 12). Furthermore, epidemiological studies and a
mathematical modeling study have demonstrated that CA-CDI importation into the
hospital may play a role in maintaining HA-CDI transmission (13–15).
Despite the growing evidence that HA-CDI, CA-CDI, and asymptomatic TCD coloni-
zation are interrelated and all three play a signiﬁcant role in C. difﬁcile epidemiology, no
reported study has previously evaluated these three components of C. difﬁcile at the
same time. Therefore, the current study aimed to determine whether these three
components are in fact interrelated by comparing the predominant C. difﬁcile ribotypes
and the characteristics of symptomatic and asymptomatic patients in the health care
setting and in the community over a 3-year period.
RESULTS
Over the 3-year study period, 324 patients (96 with HA-CDI, 152 with CA-CDI, and 76
with asymptomatic TCD colonization) were enrolled. One hundred sixty-ﬁve patients
(50.9%) were enrolled in Queensland, Australia, while 159 (49.1%) were enrolled in
Western Australia.
Characteristics of C. difﬁcile isolates. Five different toxin proﬁles were identiﬁed
among the toxigenic C. difﬁcile strains isolated (Table 1). The proportion of toxin proﬁles
did not signiﬁcantly differ between C. difﬁcile categories (P 0.816). The most common
toxin proﬁle was toxin A positive (A), toxin B positive (B), and CDT negative (CDT)
(n 293, 83.2%). Toxin A-negative (A), B, and CDT-positive (CDT) C. difﬁcile isolates
were recovered only from symptomatic patients (n  3), while an A, toxin B-negative
TABLE 1 Frequency distribution of C. difﬁcile toxin proﬁles by sourcea
Toxin proﬁle
No. (%) of patients
Symptomatic patientsb
Asymptomatic patients with
TCDc (n  76)HA-CDI (n  96) CA-CDI (n  152)
A, B, CDT 4 (4.2) 7 (4.6) 3 (4.0)
A, B, CDT 83 (86.5) 139 (91.4) 71 (93.4)
A, B, CDT 1 (1.0) 2 (1.3) 0 (0.0)
A, B, CDT 1 (1.0) 1 (0.7) 1 (1.3)
A, B, CDT 0 (0.0) 0 (0.0) 1 (1.3)
aHA, health care associated; CA, community associated; CDI, C. difﬁcile infection; TCDc, toxigenic C. difﬁcile
colonization.
bNontoxigenic (A, B, CDT) C. difﬁcile isolates were recovered from seven HA-CDI patients and three CA-
CDI patients.
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(B), and CDT isolate was recovered from only one asymptomatic patient. Nontoxi-
genic C. difﬁcile strains were isolated from 10 symptomatic patients (7 with HA-CDI, 3
with CA-CDI), most likely due to coinfection with TCD strains that were not isolated.
Simpson’s indices of diversity were 0.89, 0.89, and 0.88 for HA-CDI, CA-CDI, and
asymptomatic TCD colonization, respectively. Although a high diversity of ribotypes
(over 90) was identiﬁed during the study period, four C. difﬁcile ribotypes (i.e., ribotypes
014/020, 056, 002, and 018) accounted for over 50% of the isolates. C. difﬁcile ribotype
014/020 (n  97, 29.9%) was the predominant ribotype throughout the 3-year study
period among symptomatic patients (both patients with HA-CDI and patients with
CA-CDI) and asymptomatic patients (Fig. 1 and the supplemental material). C. difﬁcile
ribotype 056 (n  31, 9.6%) was the second most common ribotype isolated, followed
by ribotype 002 (n 21, 6.5%), which was predominantly found in CA-CDI patients, and
ribotype 018 (n  18, 4.9%), which was mainly found in asymptomatic TCD-colonized
patients. Among all study patients, virulent ribotypes C. difﬁcile 244, 078, 251, and 027
in particular were isolated from only four, two, one, and one CDI patients, respectively.
The predominant C. difﬁcile ribotypes isolated from symptomatic HA-CDI patients
were concordant with the ribotypes identiﬁed among asymptomatic TCD-colonized
patients; for over 70% of the isolates from symptomatic patients, an isolate with a
matching ribotype was isolated from an asymptomatic patient. Likewise, for 79% of the
C. difﬁcile isolates from the hospitals, an isolate with a matching ribotype was isolated
from the community.
Patients’ preadmission characteristics. The preadmission characteristics of the
patients constituting the three C. difﬁcile categories (HA-CDI, CA-CDI, and TCD coloni-
zation) are presented in Table 2. The proportion of females signiﬁcantly differed
between the three groups, with a higher proportion of females having CA-CDI (73.7%)
than HA-CDI (52.1%) or asymptomatic TCD colonization (52.6%) (P  0.001). Across the
three groups, there was no statistically signiﬁcant difference in health care exposure in
the previous year. With regard to medication exposure in the month prior to enroll-
ment, antimicrobials (P  0.031) and gastric acid suppressants (P value  0.001) were
more often prescribed to patients that developed HA-CDI than to the other two groups,
while laxatives (P  0.001) were more often prescribed to patients that were asymp-
tomatically colonized. The rates of household exposure to toddlers, elderly people,
domestic animals, or livestock did not signiﬁcantly differ between the groups. Ten
percent of the symptomatic patients (HA-CDI patients [10.4%] and CA-CDI patients
[10.0%]) reported having an episode of CDI in the past 12 months, whereas none of the
asymptomatic TCD-colonized patients reported such an episode (P  0.001).
FIG 1 Distribution of ribotypes by year among symptomatic HA-CDI and CA-CDI patients and asymp-
tomatic toxigenic C. difﬁcile-colonized (TCDc) patients. Ribotypes found at a frequency of less than 3
isolates in a year were grouped into the other category.
Furuya-Kanamori et al. Journal of Clinical Microbiology
January 2017 Volume 55 Issue 1 jcm.asm.org 218
 o
n






Characteristics during admission and prior to specimen collection. The reason
for admission and the procedures, comorbidities, and medication exposure that oc-
curred during admission are described in Table 3. More patients with HA-CDI (11.5%)
than asymptomatic TCD-colonized patients (1.4%) underwent a colonoscopy (P 
0.006); however, more asymptomatic TCD-colonized patients than HA-CDI patients
required mechanical ventilation (P 0.006) and underwent orthopedic (P 0.001) and
neurological (P  0.001) interventions. Signiﬁcantly lower proportions of patients with
HA-CDI than asymptomatic TCD-colonized patients presented with chronic obstructive
pulmonary disease (COPD) (P  0.026) and neurological disorders (P  0.042). Con-
versely, a higher proportion of patients with HA-CDI (16.7%) than asymptomatic
colonized patients (4.1%) had inﬂammatory bowel disease (P  0.008). In terms of
medication exposure during the hospital admission, HA-CDI patients (74.0%) and
TCD-colonized patients (77.6%) were equally exposed to antimicrobials (P  0.578).
However, penicillins and -lactamase inhibitors (P 0.010) were more often prescribed
to patients who went on to develop HA-CDI than asymptomatic TCD-colonized pa-
tients. HA-CDI patients were more likely than asymptomatic TCD-colonized patients to
have had chemotherapy (P 0.019) and antidiarrheal medication (P 0.019), while the
latter group of patients was more commonly exposed to laxatives (P  0.029).
Predictors of symptomatic and severe forms of the disease. The multivariate
logistic regression model (Table 4) revealed that patients exposed to antimicrobials
within 30 days prior to hospitalization were at a higher risk of developing symptoms
(odds ratio [OR], 2.94; 95% conﬁdence interval [CI], 1.20 to 7.14), whereas patients with
COPD were at lower risk of developing symptoms of the infection (OR, 0.31; 95% CI, 0.12
to 0.83).


















No. (%) of female patients 50 (52.1) 112 (73.7) 40 (52.6) 0.001 0.943 0.001
Median (IQR) age (yr) 61.7 (49.2–75.0) 66.4 (49.1–75.4) 66.2 (54.8–76.8) 0.765 0.317 0.607
Health care exposure 12 mo prior to enrollment
No. (%) of patients admitted to a hospital 62 (69.7) 105 (69.1) 47 (64.4) 0.924 0.476 0.729
Median (SD) no. of admissions 2.1 (2.2) 1.5 (1.6) 2.0 (2.6) 0.128 0.328 0.323
Median (IQR) LOS in the last admission 7 (4–16) 6 (3–10) 6 (3–9) 0.191 0.140 0.215
No. (%) of patients with medication exposure
30 days prior to enrollment
Antimicrobials 83 (86.5) 117 (77.0) 51 (69.9) 0.066 0.008 0.031
Gastric acid suppressants 52 (54.7) 34 (22.4) 29 (40.3) 0.001 0.64 0.001
Laxatives 28 (29.2) 17 (14.2) 29 (51.8) 0.007 0.005 0.001
No. (%) of patients with the following
household exposure prior to enrollment:
People 2 yr old 3 (3.1) 6 (4.0) 4 (5.3) 1.000 0.365 0.817
People 65 yr old 24 (25.3) 52 (34.2) 22 (29.3) 0.138 0.553 0.322
Cats 21 (21.9) 23 (15.1) 12 (15.8) 0.176 0.314 0.363
Dogs 30 (31.3) 63 (41.5) 28 (36.8) 0.106 0.441 0.269
Livestock 8 (8.3) 15 (9.9) 7 (9.2) 0.685 0.840 0.921
No. (%) of patients with the following smoking
status:
Current 8 (8.3) 10 (6.6) 7 (9.3) 0.604 0.819 0.740
Ever 52 (54.2) 61 (40.1) 43 (58.1) 0.031 0.608 0.016
No. (%) of patients with history of CDI in past
year
10 (10.4) 15 (10.0) 0 (0.0) 0.916 0.003 0.001
aHA, health care associated; CA, community associated; CDI, C. difﬁcile infection; TCDc, toxigenic C. difﬁcile colonization; IQR, interquartile range; LOS, length of stay.
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TABLE 3 Reason for admission and procedures, comorbidities, and medication exposure
during admission but prior to specimen collection among patients with HA-CDI and
asymptomatic toxigenic C. difﬁcile colonizationa
Characteristic
No. (%) of patients
P value
Symptomatic patients
with HA-CDI (n  96)
Asymptomatic patients
with TCDc (n  76)
Reason for admission
New medical/surgical problem 25 (28.1) 35 (47.3) 0.022
Exacerbation of chronic condition 25 (28.1) 19 (25.7)
Infection 31 (34.8) 12 (16.2)
Elective surgery 8 (9.0) 8 (10.8)
Medical procedures
Insertion of orogastric tubes 8 (8.3) 8 (10.8) 0.680
Gastroscopy 13 (13.5) 4 (5.4) 0.049
Colonoscopy 11 (11.5) 1 (1.4) 0.006
Mechanical ventilationb 2 (2.1) 10 (13.5) 0.006
Surgical procedures
Orthopedic 7 (7.3) 19 (25.0) 0.001
Abdominal 12 (12.5) 6 (7.9) 0.327
Cardiological/thoracic 2 (2.1) 4 (5.3) 0.238
Neurological 0 (0.0) 11 (14.5) 0.001
Oncological 5 (5.2) 0 (0.0) 0.052
Other surgical procedures 2 (2.1) 5 (6.6) 0.138
Medical conditions
Cancer 42 (43.8) 22 (29.7) 0.061
Diabetes mellitus 21 (21.9) 18 (24.3) 0.706
Neurological disorder 17 (17.7) 23 (31.1) 0.042
Gastroesophageal reﬂux disease 26 (27.1) 24 (32.4) 0.448
Chronic obstructive pulmonary
disease
10 (10.4) 17 (23.0) 0.026
Chronic kidney disease 22 (22.9) 14 (18.9) 0.527
Congestive heart failure 11 (11.5) 12 (16.2) 0.369
Liver disease 10 (10.4) 4 (5.4) 0.274
Inﬂammatory bowel disease 16 (16.7) 3 (4.1) 0.008
Diverticulosis 9 (9.4) 2 (2.7) 0.072
Solid organ transplant 7 (7.3) 1 (1.4) 0.069
Medication exposure
Any antimicrobialc 71 (74.0) 59 (77.6) 0.578
Penicillins and -lactamase
inhibitors
45 (46.9) 21 (27.6) 0.010
Cephalosporins 29 (30.2) 34 (44.7) 0.050
Penicillins 11 (11.5) 12 (15.8) 0.407
Trimethoprim-sulfamethoxazole 11 (11.5) 6 (7.9) 0.437
Carbapenems 11 (11.5) 6 (7.9) 0.437
Ciproﬂoxacin 9 (9.4) 5 (6.6) 0.354
Aminoglycosides 8 (8.3) 5 (6.6) 0.448
Fluoroquinolonesd 1 (1.0) 3 (4.0) 0.228
Clindamycin 1 (1.0) 4 (5.3) 0.120
Tetracyclines 1 (1.0) 0 (0.0) 0.442
Macrolides 0 (0.0) 3 (4.0) 0.084
Metronidazole 17 (17.7) 7 (9.2) 0.110
Vancomycin 7 (7.3) 6 (7.9) 0.882
Gastric acid-suppressive agents 59 (61.5) 41 (54.0) 0.321
Proton pump inhibitors 57 (59.4) 37 (48.7) 0.162
H2 blocker 4 (4.2) 5 (6.6) 0.480
Laxatives 28 (29.2) 34 (45.3) 0.029
Nonsteroidal anti-inﬂammatory
drugs
18 (18.8) 13 (17.1) 0.780
Glucocorticoids 35 (36.5) 18 (23.7) 0.072
Chemotherapy 12 (12.5) 2 (2.6) 0.019
Antidiarrheal medication 12 (12.5) 2 (2.6) 0.019
aHA, health care associated; CDI, C. difﬁcile infection; TCDc, toxigenic C. difﬁcile colonization.
bExcludes mechanical ventilation during surgical procedures.
cExcludes metronidazole and vancomycin.
dCiproﬂoxacin not included.
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During the follow-up period, four TCD-colonized patients developed symptomatic
CDI. Fifty-three and six patients with HA-CDI and CA-CDI, respectively, had recurrent
CDI. Nine deaths were recorded, including three among participants with HA-CDI, two
among participants with CA-CDI, and four among participants asymptomatically colo-
nized with TCD. Three patients, all with HA-CDI, were admitted to an intensive care unit
(ICU). No colectomies were recorded.
DISCUSSION
Previous studies that examined the relationship between C. difﬁcile strains and the
development of symptoms were conducted during an outbreak (16) or in settings
where binary toxin-producing C. difﬁcile strains were predominant (6); this is the ﬁrst
epidemiological study of C. difﬁcile that was conducted simultaneously in a health care
setting and a community setting and that examined symptomatic and asymptomatic
patients in a setting without establishment of hospital epidemics with binary toxin-
producing C. difﬁcile strains. There was no difference in the ribotype diversity of the
isolates across the HA-CDI, CA-CDI, and asymptomatic TCD-colonized patients, reﬂect-
ing similar pathogen population structures. Furthermore, the most prevalent C. difﬁcile
ribotypes were similar across the HA-CDI, CA-CDI, and asymptomatic TCD-colonized
patients, suggesting that transmission of C. difﬁcile is occurring between the hospitals
and the communities and that asymptomatic TCD-colonized individuals as well as
symptomatic patients may be acting as a vehicle of transmission between these two
settings.
The ﬁnding also suggests that C. difﬁcile ribotypes may not be determinants of the
development of symptomatic infection but, rather, that the development of symptoms
may be mainly driven by host factors, such as immune state and disruption of the gut
microbiome by exposure to antimicrobials or underlying conditions affecting the
gastrointestinal tract (17–19). Our ﬁndings differ from those of a previous study in
which a binary toxin-producing C. difﬁcile strain (i.e., ribotype 027) was more likely than
other strains to cause symptomatic disease (6). This difference could be explained by
the very low prevalence of C. difﬁcile ribotype 027 and other highly virulent binary
toxin-producing strains in Australia, and therefore, our ﬁndings may be expected in
other settings without hospital epidemics with binary toxin-producing C. difﬁcile strains.
Several meta-analyses have described the risk factors for HA-CDI (20) and CA-CDI
(21); however, female sex is not a well-documented risk factor for CA-CDI, and few
studies have described this association (22–26). In our study, we found that nearly
three-quarters of the CA-CDI cases occurred in women, whereas HA-CDI and asymp-
TABLE 4 Logistic regression for predictors of symptomatic HA-CDI compared to
asymptomatic toxigenic C. difﬁcile colonization
Characteristic
OR (95% CI)a
Univariate model Multivariate model
Female 0.98 (0.53–1.79) 0.92 (0.45–1.85)
Age (per decade) 0.91 (0.76–1.09) 0.96 (0.78–1.19)
Admitted to a hospital in past 12 mo 1.27 (0.66–2.44) 1.05 (0.48–2.27)
Medication exposure 30 days prior to admission
Antimicrobials 2.78 (1.28–5.88) 2.94 (1.20–7.14)
Gastric acid-suppressive agents 1.79 (0.96–3.33) 1.67 (0.76–3.57)
Medical conditions
Cancer 1.85 (0.97–3.45) 1.15 (0.52–2.50)
Diabetes mellitus 0.87 (0.43–1.79) 0.72 (0.30–1.69)
Neurological disorder 0.48 (0.23–0.98) 0.50 (0.21–1.15)
Gastroesophageal reﬂux disease 0.78 (0.40–1.49) 0.74 (0.33–1.64)
Chronic obstructive pulmonary disease 0.39 (0.17–0.91) 0.31 (0.12–0.83)
Chronic kidney disease 1.27 (0.60–2.70) 1.16 (0.47–2.86)
Congestive heart failure 0.67 (0.28–1.61) 1.03 (0.35–3.03)
aOR odds ratio; CI, conﬁdence interval. Boldface data indicate statistically signiﬁcant results.
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tomatic cases were equally distributed between the sexes. This observation may be
mostly related to behavioral risk factors among women that occur in the community
rather than physiological differences between the sexes. Among the behavioral factors
occurring in the community that may put females at risk of CDI are higher rates of
antimicrobial prescriptions (27, 28), vegetable consumption (29), and contact with
children (30).
While there is no conclusive evidence that contaminated food leads to CDI in
humans, studies have found that retail vegetables are contaminated with C. difﬁcile
strains similar to those affecting humans (31, 32). Likewise, the C. difﬁcile ribotypes
frequently isolated in the current study, such as 014/020 and 056, are common
ribotypes found in piglets and veal calves, respectively, in Australia (33, 34). Therefore,
the possibility of food being a vehicle of C. difﬁcile transmission cannot be ruled out.
Although our study did not ﬁnd an association between the CDI category and contact
with toddlers (30), this association needs to be assessed in the context of gender as an
effect modiﬁer. Due to the small number of participants that reported living with
toddlers, this analysis was not possible.
Another interesting ﬁnding was that 10% of symptomatic patients in both settings
(hospital and community) but none of the asymptomatic TCD-colonized patients
reported having had a CDI in the previous year. While this may be explained by recall
bias, given the greater awareness of the disease among the symptomatic patients, this
ﬁnding may also reﬂect differences in immune system capacity, with previous infection
not offering protection against further infection in these individuals. Those with some
degree of immunosuppression might develop symptoms, and those with a fully
functioning immune system might not develop symptoms irrespective of the toxige-
nicity of the C. difﬁcile strains to which the patient had previously been exposed. This
hypothesis warrants further investigation that would require measurement and com-
parison of the serum antibody, proinﬂammatory cytokine, and chemokine levels of
noncolonized, asymptomatic C. difﬁcile-colonized, and symptomatic CDI patients. How-
ever, indirect evidence from the current study supports our hypothesis, given that
patients with some degree of immunosuppression (patients on chemotherapy) were
more likely to develop symptoms.
This study supports reports elsewhere that inﬂammatory bowel disease is a risk
factor for developing CDI (35); however, a ﬁnding that requires further investigation is
that patients with COPD were less likely to develop symptoms. Wojciechowski and
colleagues reported a reduced risk of CDI for patients with a COPD diagnosis and when
systemic corticosteroids were used during antimicrobial treatment (36). This was cor-
roborated by the ﬁndings of the present study, whereby COPD was statistically signif-
icantly associated with a reduced risk of CDI. Wojciechowski and colleagues argued that
corticosteroids attenuate the host immune response to C. difﬁcile toxins, thus reducing
the toxin-induced cytokine release that is associated with systemic symptoms of CDI
(36). Further studies are required to conﬁrm the mechanism behind the association.
There are some limitations to this study. Although a large sample size (n  342) of
patients was enrolled, the small number of signiﬁcant health outcomes (i.e., deaths, ICU
admission) recorded during the follow-up period precluded statistical analyses to
elucidate whether HA-CDI was associated with more severe outcomes than CA-CDI. In
addition, more discriminatory strain typing methods (e.g., multilocus variable-number
tandem-repeat analysis and whole-genome sequencing) are required to conclusively
determine speciﬁc transmission events between community and hospital CDI cases as
well as the role of asymptomatic colonized patients.
In summary, similar C. difﬁcile ribotypes were circulating in the community and
hospitals in this study of two Australian states, suggesting the carryover of strains
between settings. Furthermore, asymptomatic and symptomatic patients were colo-
nized with similar C. difﬁcile ribotypes, suggesting that in a setting without establish-
ment of hospital epidemics with binary toxin-producing C. difﬁcile strains, the devel-
opment of symptoms may be primarily driven by host characteristics rather than C.
difﬁcile toxigenicity or ribotype. Future epidemiological studies in settings without
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hospital epidemics with binary toxin-producing C. difﬁcile strains are needed to conﬁrm
our ﬁndings and determine the role of patient-, antibiotic-, and C. difﬁcile strain-related
factors in the development of symptoms.
MATERIALS AND METHODS
Study setting. Two studies were simultaneously conducted over a 3-year period (2012 to 2014) in
two Australian states. The ﬁrst study examined symptomatic patients with HA-CDI and CA-CDI, whereas
the second study examined asymptomatic C. difﬁcile-colonized patients in a health care setting.
The ﬁrst study enrolled patients in two tertiary care hospitals, The Royal Brisbane and Women’s
Hospital (RBWH) with 929 beds in Brisbane, Queensland, Australia, and The Sir Charles Gairdner Hospital
(SCGH) with 607 beds in Perth, Western Australia. Patients in the community who submitted specimens
through their general practitioner (GP) to coordinating laboratories (Sullivan Nicolaides Pathology in
Brisbane, Queensland, Australia, and PathWest Laboratory Medicine, Clinipath Laboratories, and Western
Diagnostic Pathology in Perth, Western Australia, Australia) were also enrolled. This study used a census
design, in which all the stool specimens submitted during the study period to the hospitals and the
laboratories by patients 18 year of age or older and experiencing diarrhea were screened for C. difﬁcile.
If the specimen was positive for the C. difﬁcile toxin A or B gene, the patient was invited to participate
in the study. HA-CDI was deﬁned as health care facility-onset, health care facility-associated CDI
constituting the onset of diarrhea 48 h or more after admission to a hospital and as community-onset,
health care facility-associated disease constituting the onset of symptoms in a patient who had been
discharged from a health care facility within the previous 4 weeks. CA-CDI was deﬁned as community-
onset CDI in a patient who had not been admitted to a health care facility in the previous 12 weeks or
as health care facility-onset CDI within 48 h or less of admission to the hospital (37).
The second study has been previously described elsewhere (38). In brief, six cross-sectional surveys
(two per year) were conducted at RBWH and SCGH. Randomly selected hospitalized patients aged 18
years or older without diarrhea were approached and invited to participate in the study. Patients who
were not experiencing diarrhea and who had a toxigenic C. difﬁcile strain (positive for the presence of
tcdA, tcdB, and/or the cdtA and cdtB genes) isolated from their stool were considered to have asymp-
tomatic TCD colonization and were included in the current analysis.
The studies received the approval of RBWH (approval no. HREC/11/QRBW/223), the Sir Charles
Gairdner Group (approval no. 2011-088), The University of Queensland (approval no. 2011000898), and
The University of Western Australia (approval no. RA/4/1/5186) Human Research Ethics Committees. All
the participants (or a legal proxy) provided written informed consent for their inclusion in the study. In
Western Australia, a waiver of consent was granted when a person was unable to provide consent but
the person could be enrolled in the study without any additional risk beyond that associated with their
standard care.
Data collection. A questionnaire with questions regarding the patient’s age, sex, occupation,
previous hospital admissions, and use of medications in the previous 30 days and his or her cohabitants’
ages was administered to all patients from both studies. For hospitalized patients at RBWH and SCGH,
medical records were accessed to obtain additional information and to determine the date and the
reason for the current admission, comorbidities, as well as the inpatient medications provided and
procedures performed prior to specimen collection. Each participant was followed up on a monthly basis
for 3 months by examination of the patient’s records and a short interview for hospital patients and by
a telephone interview for discharged or CA-CDI cases. The follow-up interviews were used to determine
the clinical outcomes of the patients (whether they developed symptoms, had a recurrence of CDI,
underwent a colectomy, were admitted to an ICU, or died).
Stool specimen collection and processing. As previously described (38), direct stool specimen
culture was performed on ChromID C. difﬁcile agar (bioMérieux). Broth enrichment in Robertson’s cooked
meat medium followed by ethanol shock and subculture on ChromID C. difﬁcile agar at 48 to 72 h was
performed if the direct culture result was negative. Putative C. difﬁcile colonies were subcultured onto
prereduced blood agar plates under anaerobic conditions. C. difﬁcile isolates were tested for the presence
of toxin genes and were ribotyped by PCR as previously described (39). Strains that did not produce
banding patterns matching the pattern for an international ribotype in the reference collection were
assigned a local nomenclature (QX type).
Statistical analysis. The frequency of C. difﬁcile ribotypes was tabulated by year and C. difﬁcile
category (HA-CDI, CA-CDI, and asymptomatic TCD colonization) to identify the predominant ribotypes
circulating in each category and to examine the changes in ribotype proﬁle over the study period.
Simpson’s index of diversity was calculated for each category to compare the diversity of ribotypes
isolated across the three categories.
Pearson’s chi-square test and Fisher’s exact test were used to compare categorical variables, whereas
the Wilcox-Mann-Whitney U test and Kruskal-Wallis H test were used to compare continuous variables
between participant groups. Multivariate logistic regression models were built to identify predictors of
symptomatic disease. After adjustment for the age and sex of the patients and known risk factors for CDI
(i.e., prior hospital admissions and exposure to antimicrobials and gastric acid-suppressive agents), the
inclusion of comorbidities in the regression model was done through a stepwise forward selection by use
of the Akaike information criterion as the selection criterion. A signiﬁcance level cutoff of a P value of 0.05
was used for all analyses. All statistical analyses were conducted using Stata SE, version 14 (Stata
Corporation, College Station, TX).
C. difﬁcile Ribotypes in Australia Journal of Clinical Microbiology
January 2017 Volume 55 Issue 1 jcm.asm.org 223
 o
n







Supplemental material for this article may be found at https://doi.org/10.1128/
JCM.01779-16.
TEXT S1, PDF ﬁle, 0.05 MB.
ACKNOWLEDGMENTS
We thank all patients, physicians, nurses, laboratories, and hospitals who took part
in the study. We also thank Tanya Scheller, Christine Duncan, Suzanne Ditchburn,
Welma Van Schalkwyk, Noellene Foster, Sarah MacArthur, and Jessica Macfarlane, who
assisted with the enrollment of the patients and data extraction.
This research was funded by a National Health and Medical Research Council grant
(1006243). L.F.-K. is funded by an Endeavor postgraduate scholarship (3781_2014), an
Australian National University higher degree scholarship, and a Fondo para la Inno-
vación, Ciencia y Tecnología scholarship (095-FINCyT-BDE-2014). A.C.A.C. is funded by
an Australian National Health and Medical Research Council senior research fellowship
(1058878).
The study sponsors had no further role in the study design, data collection, analyses,
interpretation of results, writing of the article, or the decision to submit it for publica-
tion.
We have no competing interests.
REFERENCES
1. Goorhuis A, Bakker D, Corver J, Debast SB, Harmanus C, Notermans DW,
Bergwerff AA, Dekker FW, Kuijper EJ. 2008. Emergence of Clostridium
difﬁcile infection due to a new hypervirulent strain, polymerase chain
reaction ribotype 078. Clin Infect Dis 47:1162–1170. https://doi.org/
10.1086/592257.
2. Borgmann S, Kist M, Jakobiak T, Reil M, Scholz E, von Eichel-Streiber C,
Gruber H, Brazier JS, Schulte B. 2008. Increased number of Clostridium
difﬁcile infections and prevalence of Clostridium difﬁcile PCR ribotype
001 in southern Germany. Euro Surveill 13(49):pii19057. http://
www.eurosurveillance.org/ViewArticle.aspx?ArticleId19057.
3. Loo VG, Poirier L, Miller MA, Oughton M, Libman MD, Michaud S,
Bourgault AM, Nguyen T, Frenette C, Kelly M, Vibien A, Brassard P, Fenn
S, Dewar K, Hudson TJ, Horn R, Rene P, Monczak Y, Dascal A. 2005. A
predominantly clonal multi-institutional outbreak of Clostridium
difﬁcile-associated diarrhea with high morbidity and mortality. N Engl J
Med 353:2442–2449. https://doi.org/10.1056/NEJMoa051639.
4. Centers for Disease Control and Prevention. 2005. Severe Clostridium
difﬁcile-associated disease in populations previously at low risk—four
states, 2005. Morb Mortal Wkly Rep 54:1201–1205.
5. Centers for Disease Control and Prevention. 2008. Surveillance for
community-associated Clostridium difﬁcile—Connecticut, 2006. Morb
Mortal Wkly Rep 57:340–343.
6. Loo VG, Bourgault A-M, Poirier L, Lamothe F, Michaud S, Turgeon N, Toye
B, Beaudoin A, Frost EH, Gilca R, Brassard P, Dendukuri N, Béliveau C,
Oughton M, Brukner I, Dascal A. 2011. Host and pathogen factors for
Clostridium difﬁcile infection and colonization. N Engl J Med 365:
1693–1703. https://doi.org/10.1056/NEJMoa1012413.
7. Riley TV, Thean S, Hool G, Golledge CL. 2009. First Australian isolation of
epidemic Clostridium difﬁcile PCR ribotype 027. Med J Aust 190:
706–708.
8. Richards M, Knox J, Elliott B, Mackin K, Lyras D, Waring LJ, Riley TV. 2011.
Severe infection with Clostridium difﬁcile PCR ribotype 027 acquired in
Melbourne, Australia. Med J Aust 194:369–371.
9. Huber CA, Hall L, Foster NF, Gray M, Allen M, Richardson LJ, Robson J,
Vohra R, Schlebusch S, George N, Nimmo GR, Riley TV, Paterson DL. 2014.
Surveillance snapshot of Clostridium difﬁcile infection in hospitals across
Queensland detects binary toxin producing ribotype UK 244. Commun
Dis Intell Q Rep 38:E279–E284.
10. Foster NF, Collins DA, Ditchburn SL, Duncan CN, van Schalkwyk JW,
Golledge CL, Keed AB, Riley TV. 2014. Epidemiology of Clostridium
difﬁcile infection in two tertiary-care hospitals in Perth, Western
Australia: a cross-sectional study. New Microbes New Infect 2:64–71.
https://doi.org/10.1002/nmi2.43.
11. Lanzas C, Dubberke ER, Lu Z, Reske KA, Grohn YT. 2011. Epidemiological
model for Clostridium difﬁcile transmission in healthcare settings. Infect
Control Hosp Epidemiol 32:553–561. https://doi.org/10.1086/660013.
12. Clabots CR, Johnson S, Olson MM, Peterson LR, Gerding DN. 1992.
Acquisition of Clostridium difﬁcile by hospitalized patients: evidence for
colonized new admissions as a source of infection. J Infect Dis 166:
561–567. https://doi.org/10.1093/infdis/166.3.561.
13. Walker AS, Eyre DW, Wyllie DH, Dingle KE, Harding RM, O’Connor L,
Grifﬁths D, Vaughan A, Finney J, Wilcox MH, Crook DW, Peto TE. 2012.
Characterisation of Clostridium difﬁcile hospital ward-based transmis-
sion using extensive epidemiological data and molecular typing. PLoS
Med 9:e1001172. https://doi.org/10.1371/journal.pmed.1001172.
14. Yakob L, Riley T, Paterson D, Clements A. 2013. Clostridium difﬁcile
exposure as an insidious source of infection in healthcare settings: an
epidemiological model. BMC Infect Dis 13:376. https://doi.org/10.1186/
1471-2334-13-376.
15. Curry SR, Muto CA, Schlackman JL, Pasculle AW, Shutt KA, Marsh JW,
Harrison LH. 2013. Use of multilocus variable number of tandem repeats
analysis genotyping to determine the role of asymptomatic carriers in
Clostridium difﬁcile transmission. Clin Infect Dis 57:1094–1102. https://
doi.org/10.1093/cid/cit475.
16. Johnson S, Clabots CR, Linn FV, Olson MM, Peterson LR, Gerding DN.
1990. Nosocomial Clostridium difﬁcile colonisation and disease. Lancet
336:97–100. https://doi.org/10.1016/0140-6736(90)91605-A.
17. Walk ST, Micic D, Jain R, Lo ES, Trivedi I, Liu EW, Almassalha LM, Ewing
SA, Ring C, Galecki AT, Rogers MA, Washer L, Newton DW, Malani PN,
Young VB, Aronoff DM. 2012. Clostridium difﬁcile ribotype does not
predict severe infection. Clin Infect Dis 55:1661–1668. https://doi.org/
10.1093/cid/cis786.
18. Walker AS, Eyre DW, Crook DW, Wilcox MH, Peto TEA. 2013. Regarding
“Clostridium difﬁcile ribotype does not predict severe infection.” Clin
Infect Dis 56:1845–1846. https://doi.org/10.1093/cid/cit098.
19. Walker AS, Eyre DW, Wyllie DH, Dingle KE, Grifﬁths D, Shine B, Oakley S,
O’Connor L, Finney J, Vaughan A, Crook DW, Wilcox MH, Peto TE. 2013.
Relationship between bacterial strain type, host biomarkers, and mor-
tality in Clostridium difﬁcile infection. Clin Infect Dis 56:1589–1600.
https://doi.org/10.1093/cid/cit127.
20. Slimings C, Riley TV. 2014. Antibiotics and hospital-acquired Clostridium
difﬁcile infection: update of systematic review and meta-analysis. J
Antimicrob Chemother 69:881–891. https://doi.org/10.1093/jac/dkt477.
21. Furuya-Kanamori L, Stone JC, Clark J, McKenzie SJ, Yakob L, Paterson DL,
Riley TV, Doi SA, Clements AC. 2015. Comorbidities, exposure to medi-
cations, and the risk of community-acquired Clostridium difﬁcile
Furuya-Kanamori et al. Journal of Clinical Microbiology
January 2017 Volume 55 Issue 1 jcm.asm.org 224
 o
n






infection: a systematic review and meta-analysis. Infect Control Hosp
Epidemiol 36:132–141. https://doi.org/10.1017/ice.2014.39.
22. Dial S, Delaney JC, Barkun AN, Suissa S. 2005. Use of gastric acid-
suppressive agents and the risk of community-acquired Clostridium
difﬁcile-associated disease. JAMA 294:2989–2995. https://doi.org/
10.1001/jama.294.23.2989.
23. Itskowitz MS, Lebovitz PJ. 2003. Non-antibiotic associated pseudomem-
branous colitis: a case report and review of the literature. Adv Stud Med
3:571–574.
24. Chen Y, Glass K, Liu B, Riley T, Korda R, Kirk M. 26 October 2016. A
population-based longitudinal study of Clostridium difﬁcile infection-
related hospitalization in mid-age and older Australians. Epidemiol In-
fect. Epub ahead of print.
25. Aronsson B, Mollby R, Nord CE. 1982. Clostridium difﬁcile and antibiotic
associated diarrhoea in Sweden. Scand J Infect Dis Suppl 35:53–58.
26. Chitnis AS, Holzbauer SM, Belﬂower RM, Winston LG, Bamberg WM,
Lyons C, Farley MM, Dumyati GK, Wilson LE, Beldavs ZG, Dunn JR, Gould
LH, MacCannell DR, Gerding DN, McDonald LC, Lessa FC. 2013. Epide-
miology of community-associated Clostridium difﬁcile infection, 2009
through 2011. JAMA Intern Med 173:1359–1367. https://doi.org/
10.1001/jamainternmed.2013.7056.
27. Barlam TF, Morgan JR, Wetzler LM, Christiansen CL, Drainoni ML. 2015.
Antibiotics for respiratory tract infections: a comparison of prescribing in
an outpatient setting. Infect Control Hosp Epidemiol 36:153–159.
https://doi.org/10.1017/ice.2014.21.
28. Sun C, Jew S, Dasta SL. 2006. Osteopathic physicians in the United
States: antibiotic prescribing practices for patients with nonspeciﬁc
upper respiratory tract infections. J Am Osteopath Assoc 106:450–455.
29. Milligan RA, Burke V, Beilin LJ, Dunbar DL, Spencer MJ, Balde E, Gracey
MP. 1998. Inﬂuence of gender and socio-economic status on dietary
patterns and nutrient intakes in 18-year-old Australians. Aust N Z J Public
Health 22:485–493. https://doi.org/10.1111/j.1467-842X.1998.tb01419.x.
30. Wilcox MH, Mooney L, Bendall R, Settle CD, Fawley WN. 2008. A case-
control study of community-associated Clostridium difﬁcile infection. J
Antimicrob Chemother 62:388–396. https://doi.org/10.1093/jac/dkn163.
31. Metcalf DS, Costa MC, Dew WM, Weese JS. 2010. Clostridium difﬁcile in
vegetables, Canada. Lett Appl Microbiol 51:600–602. https://doi.org/
10.1111/j.1472-765X.2010.02933.x.
32. Bakri MM, Brown DJ, Butcher JP, Sutherland AD. 2009. Clostridium
difﬁcile in ready-to-eat salads, Scotland. Emerg Infect Dis 15:817. https://
doi.org/10.3201/eid1505.081186.
33. Knight DR, Thean S, Putsathit P, Fenwick S, Riley TV. 2013. Cross-
sectional study reveals high prevalence of Clostridium difﬁcile non-PCR
ribotype 078 strains in Australian veal calves at slaughter. Appl Environ
Microbiol 79:2630–2635. https://doi.org/10.1128/AEM.03951-12.
34. Knight DR, Squire MM, Riley TV. 2015. Nationwide surveillance study of
Clostridium difﬁcile in Australian neonatal pigs shows high prevalence
and heterogeneity of PCR ribotypes. Appl Environ Microbiol 81:119–123.
https://doi.org/10.1128/AEM.03032-14.
35. Rodemann JF, Dubberke ER, Reske KA, Seo DH, Stone CD. 2007. Inci-
dence of Clostridium difﬁcile infection in inﬂammatory bowel disease.
Clin Gastroenterol Hepatol 5:339–344. https://doi.org/10.1016/j.cgh
.2006.12.027.
36. Wojciechowski AL, Parameswaran GI, Mattappallil A, Mergenhagen KA.
2014. Corticosteroid use is associated with a reduced incidence of
Clostridium difﬁcile-associated diarrhea: a retrospective cohort study.
Anaerobe 30:27–29. https://doi.org/10.1016/j.anaerobe.2014.07.010.
37. Cohen SH, Gerding DN, Johnson S, Kelly CP, Loo VG, McDonald LC, Pepin
J, Wilcox MH. 2010. Clinical practice guidelines for Clostridium difﬁcile
infection in adults: 2010 update by the Society for Healthcare Epidemi-
ology of America (SHEA) and the Infectious Diseases Society of America
(IDSA). Infect Control Hosp Epidemiol 31:431–455. https://doi.org/
10.1086/651706.
38. Furuya-Kanamori L, Clements AC, Foster NF, Huber CA, Hong S, Harris-
Brown T, Yakob L, Paterson D, Riley TV. 8 September 2016. Asymptom-
atic Clostridium difﬁcile colonisation in two Australian tertiary hospitals,
2012-2014: a prospective, repeated cross-sectional study. Clin Microbiol
Infect. https://doi.org/10.1016/j.cmi.2016.08.030.
39. Carson KC, Boseiwaqa LV, Thean SK, Foster NF, Riley TV. 2013. Isolation
of Clostridium difﬁcile from faecal specimens—a comparison of Chro-
mID C. difﬁcile agar and cycloserine-cefoxitin-fructose agar. J Med Mi-
crobiol 62:1423–1427. https://doi.org/10.1099/jmm.0.056515-0.
C. difﬁcile Ribotypes in Australia Journal of Clinical Microbiology
January 2017 Volume 55 Issue 1 jcm.asm.org 225
 o
n
 June 14, 2017 by UQ Library
http://jcm.asm.org/
D
ow
nloaded from
 
